

# Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Last Update: Apr 24, 2025

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer

ClinicalTrials.gov Identifier:

[NCT05803941](#)

Novartis Reference Number: CAAA617A12402

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## Study Description

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as  $[^{177}\text{Lu}]\text{Lu-PSMA-617}$  or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials. This is a global, prospective, multi-center, long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.

There will be no study treatment administered to participants in this study. Participants will have visits every 6-8 months for monitoring of selected AEs and laboratory parameters. The study periods include a Baseline and Follow-up Period (up to 10 years after first dose of AAA617 in parent treatment study).

Participants should enroll into the LTFU study after parent treatment study requirements are fulfilled (refer to the parent treatment study protocol for requirements, including any additional requirements after participant enters this LTFU safety study).

The schedule of activities for this LTFU study is designed to start from date of informed consent for this LTFU study. Participants should be followed every 6 to 8 months for up to a total of 10 years starting from first dose of AAA617 in the parent treatment study. Participants entering the LTFU study will have already completed a variable portion of the required 10-year follow-up within the parent treatment study. The specific number of visits required in this LTFU study will depend upon the time of enrollment into this LTFU study following the first dose of AAA617 in the parent treatment study.

The total number of participants to be enrolled and the duration of this LTFU study will depend upon the total number treated in the parent treatment studies and their duration.

Condition

Prostate Cancer

Phase  
Phase4  
Overall Status  
Recruiting  
Number of Participants  
700  
Start Date  
Aug 14, 2023  
Completion Date  
Jul 21, 2033  
Gender  
Male  
Age(s)  
18 Years - 100 Years (Adult, Older Adult)

## Interventions

Drug

### **AAA617**

Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.

## Eligibility Criteria

Inclusion Criteria:

- \* Signed informed consent must be obtained prior to participation in the study
- \* Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.

Exclusion Criteria:

- Inability to complete the needed investigational examinations due to any reason.

### **Austria**

#### **Novartis Investigative Site**

Recruiting

Linz,4020,Austria

#### **Novartis Investigative Site**

Recruiting

Wien,1090,Austria

## **Belgium**

### **Novartis Investigative Site**

Recruiting

Gent,9000,Belgium

## **Canada**

### **Novartis Investigative Site**

Recruiting

Montreal,Quebec,H2x 1r9,Canada

## **Czechia**

### **Novartis Investigative Site**

Recruiting

Olomouc,779 00,Czechia

### **Novartis Investigative Site**

Recruiting

Praha 5,150 06,Czechia

## **France**

### **Novartis Investigative Site**

Recruiting

Lyon,69373,France

## **Germany**

### **Novartis Investigative Site**

Recruiting

Essen,45147,Germany

### **Novartis Investigative Site**

Recruiting

Muenchen,80377,Germany

### **Novartis Investigative Site**

Recruiting

Rostock,18057,Germany

## **Netherlands**

### **Novartis Investigative Site**

Recruiting

Delft,2625 ad,Netherlands

### **Novartis Investigative Site**

Recruiting

Maastricht,6229 hx,Netherlands

### **Novartis Investigative Site**

Recruiting

Nijmegen,6500hb,Netherlands

## **Spain**

### **Novartis Investigative Site**

Recruiting

Madrid,28034,Spain

### **Novartis Investigative Site**

Recruiting

Madrid,28040,Spain

### **Novartis Investigative Site**

Recruiting

Madrid,28041,Spain

### **Novartis Investigative Site**

Recruiting

Sabadell,Barcelona,08208,Spain

### **Novartis Investigative Site**

Recruiting

Madrid,28046,Spain

**Novartis Investigative Site**

Recruiting

Barcelona,Catalunya,08035,Spain

**Novartis Investigative Site**

Recruiting

Madrid,28222,Spain

**Novartis Investigative Site**

Recruiting

Barcelona,Catalunya,08036,Spain

**Novartis Investigative Site**

Recruiting

Valencia,46026,Spain

**Novartis Investigative Site**

Recruiting

Hospitalet de Llobregat,Catalunya,08907,Spain

**Sweden**

**Novartis Investigative Site**

Recruiting

Goteborg,413 45,Sweden

**Novartis Investigative Site**

Recruiting

Stockholm,17176,Sweden

**United Kingdom**

**Novartis Investigative Site**

Recruiting

Middlesbrough,Ts4 3bw,United Kingdom

**Novartis Investigative Site**

Recruiting

Sutton,Surrey,Sm2 5pt,United Kingdom

**Novartis Investigative Site**

Recruiting

Barnet,En5 3dj,United Kingdom

**Novartis Investigative Site**

Recruiting

Cambridge,Cb2 0qq,United Kingdom

**Novartis Investigative Site**

Recruiting

Glasgow,G12 0yn,United Kingdom

**United States****Cleveland Clinic Foundation**

Recruiting

Cleveland,Ohio,44195,United States

Phone: 216-444-0441

Shilpa Gupta

**Ochsner Clinic Foundation**

Recruiting

New Orleans,Louisiana,70121,United States

Phone: 504-842-6044

Stephen Bardot

**University Cancer and Blood Center LLC**

Recruiting

Athens,Georgia,30607,United States

Petros Nikolinakos

Phone: 706-353-2990

**Nebraska Cancer Specialists**

Recruiting

Omaha,Nebraska,68154,United States

Ralph Hauke

**Mayo Clinic Arizona**

Recruiting

Scottsdale,Arizona,85259,United States

Phone: 480-301-8300

Cassandra Moore

**St. Joseph Hospital**

Recruiting

Orange,California,92686,United States

Timothy Byun

**Parkview Research Center**

Recruiting

Fort Wayne,Indiana,46845,United States

Brian Chang

**Montefiore Medical Center**

Recruiting

Bronx,New York,10467,United States

Benjamin A Gartrell

**Onco Hemato Asso of SE Virginia**

Recruiting

Roanoke,Virginia,24014,United States

Phone: 540-774-8660

David Buck

## **Providence Saint Johns Health Ctr**

Recruiting

Santa Monica, California, 90404, United States

Przemyslaw Twardowski

## **University of Mississippi Med Ctr**

Recruiting

Jackson, Mississippi, 39216, United States

Phone: +1 601 815 5374

John Clark Henegan

## **Corewell Health William Beaum Hosp**

Recruiting

Royal Oak, Michigan, 48073-6769, United States

Andrew Thompson

## **Duke University Medical Center**

Recruiting

Durham, North Carolina, 27710, United States

Daniel J. George

## **VA Medical Center**

Recruiting

Washington, District of Columbia, 20422, United States

Phone: 202-745-8457

Frank Liu

## **University of Colorado**

Recruiting

Aurora, Colorado, 80045, United States

Muthiah Nachiappan

## **Mayo Clinic Rochester**



Recruiting

Rochester,Minnesota,55905,United States

Brian Costello

### **Univ of Pittsburgh Medical Center**

Recruiting

Pittsburgh,Pennsylvania,15232,United States

Leonard Appleman

### **Hartford Hospital**

Recruiting

Hartford,Connecticut,06102,United States

Andrew Salner

### **Urology Cancer Center PC**

Recruiting

Omaha,Nebraska,68130,United States

Phone: 402-697-2229

Luke Nordquist

### **Wash U School of Medicine**

Recruiting

Saint Louis,Missouri,63110,United States

Hyun Kim

Lindsey Mayer

Email: [lindseymayer@wustl.edu](mailto:lindseymayer@wustl.edu)

### **Univ of Texas Southwest Med Center**

Recruiting

Dallas,Texas,75390-9034,United States

Kevin Courtney

### **Tulane Cancer Center**

Recruiting

New Orleans,Louisiana,70112,United States

Phone: 504-585-6077

Brian Lewis

### **Mayo Clinic Jacksonville**

Recruiting

Jacksonville,Florida,32224,United States

Winston Tan

### **UT Health Science Center**

Recruiting

Houston,Texas,77030,United States

Bo Chen

## **Worldwide Contacts**

If the location of your choosing does not feature any contact detail, please reach out using the information below.

### **Novartis Pharmaceuticals**

Phone: +41613241111

Email: novartis.email@novartis.com

### **Novartis Pharmaceuticals**

Phone: 1-888-669-6682

Email: novartis.email@novartis.com

---

**Source URL:** <https://prod1.novartis.com/clinicaltrials/study/nct05803941>

### **List of links present in page**

1. <https://clinicaltrials.gov/ct2/show/NCT05803941>
2. [#trial-eligibility](#)
3. <tel:216-444-0441>
4. <tel:504-842-6044>
5. <tel:706-353-2990>
6. <tel:480-301-8300>
7. <tel:540-774-8660>
8. [tel:+1 601 815 5374](tel:+16018155374)
9. <tel:202-745-8457>
10. <tel:402-697-2229>
11. <mailto:lindseymayer@wustl.edu>

- 12. tel:504-585-6077
- 13. tel:+41613241111
- 14. mailto:novartis.email@novartis.com
- 15. tel:1-888-669-6682
- 16. mailto:novartis.email@novartis.com